Randomized, Double‐Blind, Placebo‐Controlled, Dose‐Escalating Phase I, Healthy Subjects Study of Intravenous OPN‐305, a Humanized Anti‐TLR2 Antibody

Upregulation of Toll‐like receptor 2 (TLR2) plays a critical role in inflammation associated with ischemia/reperfusion–induced tissue damage. OPN‐305 is the first humanized IgG4 monoclonal antibody against TLR2 in development and is intended for the prevention of reperfusion injury following renal t...

Full description

Saved in:

Bibliographic Details
Published in:	Clinical pharmacology and therapeutics Vol. 94; no. 5; pp. 593 - 600
Main Authors:	Reilly, M, Miller, R M, Thomson, M H, Patris, V, Ryle, P, McLoughlin, L, Mutch, P, Gilboy, P, Miller, C, Broekema, M, Keogh, B, McCormack, W, Wetering de Rooij, J
Format:	Journal Article
Language:	English
Published:	United States 01.11.2013
Subjects:	Adolescent Adult Antibodies, Monoclonal - administration & dosage Antibodies, Monoclonal - immunology Antibodies, Monoclonal - pharmacokinetics Antibodies, Monoclonal - pharmacology Dose-Response Relationship, Immunologic Double-Blind Method Humans Infusions, Intravenous Interleukin-6 - antagonists & inhibitors Interleukin-6 - blood Leukocyte Count Male Middle Aged Toll-Like Receptor 2 - immunology Young Adult
ISSN:	0009-9236, 1532-6535, 1532-6535
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!